Laboratory of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Pharmaceutical Research and Technology Labs, Astellas Pharma Inc., Shizuoka, Japan.
Biopharm Drug Dispos. 2023 Dec;44(6):387-395. doi: 10.1002/bdd.2373. Epub 2023 Aug 1.
The present study was undertaken to develop a self-micellizing solid dispersion (SMSD) of tacrolimus (TAC) to improve the biopharmaceutical properties of TAC. An SMSD formulation of TAC (SMSD/TAC) and amorphous solid dispersion formulation of TAC (ASD/TAC) were prepared with Soluplus , an amphiphilic copolymer, and hydroxypropyl cellulose, respectively. Physicochemical properties were characterized in terms of morphology, crystallinity, storage stability, interaction of TAC with Soluplus , and micelle-forming potency; pharmacokinetic behavior was also evaluated in rats. Tacrolimus in both formulations was in an amorphous state. After storage at 40°C/75% relativity humidity for 4 weeks, there were no significant changes in the crystallinity of TAC between nonaged and aged SMSD/TAC, whereas slight recrystallization was observed in aged ASD/TAC. The results of circular dichroism (CD) and infrared spectroscopic analyses were indicative of the potent drug-polymer interaction in SMSD/TAC, possibly leading to the prevention of recrystallization. Compared with other TAC samples, SMSD/TAC exhibited significant improvement in the dissolution behavior of TAC through the immediate formation of fine micelles. After the oral administration of TAC samples (10 mg TAC/kg) to rats, there was marked enhancement in systemic exposure to TAC with both formulations; in particular, SMSD/TAC achieved an increase in bioavailability ca. 20-fold higher than crystalline TAC. The SMSD approach might provide an effective dosage form for TAC with enhanced physicochemical stability and oral absorption.
本研究旨在开发他克莫司(TAC)自微乳分散体(SMSD)以改善 TAC 的生物药剂学性质。采用两亲性共聚物 Soluplus 和羟丙纤维素分别制备 TAC 的 SMSD 制剂(SMSD/TAC)和无定形固体分散体制剂(ASD/TAC)。从形态、结晶度、储存稳定性、TAC 与 Soluplus 的相互作用以及胶束形成能力等方面对物理化学性质进行了表征;还在大鼠中评价了其药代动力学行为。两种制剂中的他克莫司均处于无定形态。在 40°C/75%相对湿度下储存 4 周后,非老化和老化的 SMSD/TAC 之间 TAC 的结晶度没有明显变化,而 ASD/TAC 中观察到轻微的再结晶。圆二色性(CD)和红外光谱分析结果表明,SMSD/TAC 中存在强烈的药物-聚合物相互作用,可能导致再结晶的抑制。与其他 TAC 样品相比,SMSD/TAC 通过立即形成细胶束,显著改善了 TAC 的溶解行为。大鼠口服 TAC 样品(10mg TAC/kg)后,两种制剂均显著提高了 TAC 的全身暴露;特别是,SMSD/TAC 的生物利用度提高了约 20 倍,高于结晶 TAC。SMSD 方法可为 TAC 提供一种有效的剂型,具有增强的物理化学稳定性和口服吸收性。